Half-year report · HY
7733.TEDINET S100WYDD
Period2025-04-01 → 2025-09-30
Filed2025-11-07
StandardIFRS
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥454.4bn | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥997.3bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥474.0bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥46.1bn | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥70.5bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥44.8bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥159.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥68.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥29.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥117.9bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥49.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥29.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥49.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.38T | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥1.43T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.37T | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥651.2bn | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥681.5bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥733.6bn | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥751.7bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥703.1bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥757.2bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥733.6bn | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥751.7bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥703.1bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥147.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥252.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥245.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥340.9bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥21.1bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥190.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥93.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥50.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥65.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥30.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥77.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥211.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥156.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥26 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥102.99 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥42.24 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥25.96 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥102.8 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥42.16 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 53.0% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 52.4% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 51.4% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 10
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | −¥41m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥3.1bn |
| Gastrointestinal Solutionsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥53.4bn |
| Surgical And Interventional Solutionsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥4.2bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥49.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥387m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥9.0bn |
| Gastrointestinal Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥77.6bn |
| Surgical And Interventional Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.3bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥79.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 639
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of intangible assets inv cf IFRS | InterimDuration | -13169000000 | JPY |
| Purchase of investment securities inv cf IFRS | Prior1InterimDuration | -8458000000 | JPY |
| Purchase of investment securities inv cf IFRS | InterimDuration | -473000000 | JPY |
| Proceeds from transfer of orthopedic surgery business inv cf IFRS | Prior1InterimDuration | 2128000000 | JPY |
| Proceeds from transfer of orthopedic surgery business inv cf IFRS | InterimDuration | － | JPY |
| Payments for contingent consideration inv cf IFRS | Prior1InterimDuration | -3027000000 | JPY |
| Payments for contingent consideration inv cf IFRS | InterimDuration | -164000000 | JPY |
| Claw back from cancellation of stock acquisition agreements inv cf IFRS | Prior1InterimDuration | 4698000000 | JPY |
| Claw back from cancellation of stock acquisition agreements inv cf IFRS | InterimDuration | － | JPY |
| Other inv cf IFRS | Prior1InterimDuration | 4886000000 | JPY |
| Other inv cf IFRS | InterimDuration | -3379000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1InterimDuration | -30023000000 | JPY |
| Net cash provided by used in investing activities IFRS | InterimDuration | -50367000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | Prior1InterimDuration | － | JPY |
| Proceeds from long term borrowings fin cf IFRS | InterimDuration | 70000000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1InterimDuration | -50035000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | InterimDuration | -70000000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1InterimDuration | -9767000000 | JPY |
| Repayments of lease obligations fin cf IFRS | InterimDuration | -9956000000 | JPY |
| Dividends paid fin cf IFRS | Prior1InterimDuration | -20981000000 | JPY |
| Dividends paid fin cf IFRS | InterimDuration | -22556000000 | JPY |
| Proceeds from issuance of bonds fin cf IFRS | Prior1InterimDuration | － | JPY |
| Proceeds from issuance of bonds fin cf IFRS | InterimDuration | 29873000000 | JPY |
| Redemption of bonds fin cf IFRS | Prior1InterimDuration | － | JPY |
| Redemption of bonds fin cf IFRS | InterimDuration | -25000000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | Prior1InterimDuration | -56465000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | InterimDuration | -37036000000 | JPY |
| Decrease increase in deposit for purchase of treasury shares fin cf IFRS | Prior1InterimDuration | -18536000000 | JPY |
| Decrease increase in deposit for purchase of treasury shares fin cf IFRS | InterimDuration | -12979000000 | JPY |
| Other fin cf IFRS | Prior1InterimDuration | -957000000 | JPY |
| Other fin cf IFRS | InterimDuration | -31000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1InterimDuration | -156741000000 | JPY |
| Net cash provided by used in financing activities IFRS | InterimDuration | -77685000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1InterimDuration | -2012000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | InterimDuration | 1688000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1InterimDuration | -95064000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | InterimDuration | -105294000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 340933000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 252532000000 | JPY |
| Cash and cash equivalents IFRS | Prior1InterimInstant | 245869000000 | JPY |
| Cash and cash equivalents IFRS | InterimInstant | 147238000000 | JPY |
| Sales to external customers IFRS | Prior1InterimDuration_jpcrp040300-ssr_E02272-000GastrointestinalSolutionsReportableSegmentMember | 322421000000 | JPY |
| Sales to external customers IFRS | Prior1InterimDuration_jpcrp040300-ssr_E02272-000SurgicalAndInterventionalSolutionsReportableSegmentMember | 151323000000 | JPY |
| Sales to external customers IFRS | Prior1InterimDuration_ReportableSegmentsMember | 473744000000 | JPY |
| Sales to external customers IFRS | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 285000000 | JPY |
| Sales to external customers IFRS | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Sales to external customers IFRS | Prior1InterimDuration | 474029000000 | JPY |
| Net sales IFRS | Prior1InterimDuration_jpcrp040300-ssr_E02272-000GastrointestinalSolutionsReportableSegmentMember | 322421000000 | JPY |
| Net sales IFRS | Prior1InterimDuration_jpcrp040300-ssr_E02272-000SurgicalAndInterventionalSolutionsReportableSegmentMember | 151323000000 | JPY |
| Net sales IFRS | Prior1InterimDuration_ReportableSegmentsMember | 473744000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |